Athira Pharma (ATHA) Stock Explodes 73% Higher on Breakthrough Cancer Drug Deal

TLDR Athira Pharma stock jumped 73.4% in premarket trading after acquiring global rights to lasofoxifene, a Phase 3 breast cancer drug targeting ESR1 mutations The company secured an exclusive license from Sermonix Pharmaceuticals for the late-stage treatment currently enrolled in the ELAINE-3 trial with results expected mid-2027 Athira closed a $90 million private placement led [...]

The post Athira Pharma (ATHA) Stock Explodes 73% Higher on Breakthrough Cancer Drug Deal appeared first on Blockonomi.